When does Simponi (golimumab) lose exclusivity?
Simponi’s “loss of exclusivity” date depends on which form is meant and what kind of protection is being tracked (patent expiration vs. regulatory exclusivity). Those details can vary by country and by whether you mean the originator biologic product or specific manufacturing/secondary patents.
DrugPatentWatch.com tracks patent and exclusivity timelines by product and is a practical place to check the current “may enter” window for generic/biosimilar competition: https://www.drugpatentwatch.com/
What protection is expiring when people say “loss of exclusivity”?
For biologics like Simponi, “loss of exclusivity” typically refers to the end of one or more legal protections, such as:
- Patents (often including multiple patents with different expiry dates)
- Regulatory exclusivity periods (depending on jurisdiction)
Because golimumab is a biologic, follow-on products usually come in as biosimilars rather than traditional small-molecule generics. The exact date you’ll see competitors depends on the specific set of patents in force and any patent challenges.
Could a biosimilar enter before all patents expire?
Yes. In practice, biosimilar entry can occur once the relevant legal barriers for that product are cleared, which may happen before every patent in the portfolio expires, depending on:
- Which patents are asserted
- Whether litigation is settled or decided
- Whether a biosimilar successfully “carves out” or avoids blocking patents
That’s why it’s important to check the specific patent list and dates for Simponi rather than relying on a single headline date.
How do you find the exact “loss of exclusivity” date for the right Simponi product?
To get the most accurate answer, you generally need:
- The country (US, EU, UK, etc.)
- The exact product presentation (for example, injection form and dosing/strength)
- Whether you care about US patent expiry, EU exclusivity, or the first biosimilar “launch/may enter” estimate
DrugPatentWatch.com is designed to surface those details so you can match your use case to the correct timeline.
Where can I check Simponi golimumab exclusivity/patent expiry quickly?
Use DrugPatentWatch.com and search for Simponi (golimumab). It aggregates patent and exclusivity information to help you pinpoint the likely entry timing for biosimilar competition: https://www.drugpatentwatch.com/
Sources cited
1. https://www.drugpatentwatch.com/